First-in-Human Phase I Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics and Anti-Tumor Activity.

CONCLUSION: The tolerability profile of savolitinib was acceptable and the RP2D was established as 600 mg QD. Preliminary anti-tumor activity was demonstrated supporting further study in patients with PRCC.
PMID: 30952639 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - April 4, 2019 Category: Cancer & Oncology Authors: Gan HK, Millward MJ, Hua Y, Qi C, Sai Y, Su W, Wang J, Zhang L, Frigault MM, Morgan S, Yang L, Lickliter JD Tags: Clin Cancer Res Source Type: research